Insider Transactions in Q3 2021 at Novo Cure LTD (NVCR)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 03
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
501
-0.23%
|
$69,639
$139.23 P/Share
|
|
Sep 02
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
156
-0.21%
|
$21,528
$138.23 P/Share
|
|
Sep 02
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
181
-0.12%
|
$24,978
$138.23 P/Share
|
|
Sep 02
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
828
-1.93%
|
$114,264
$138.23 P/Share
|
|
Sep 02
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
540
-0.62%
|
$74,520
$138.23 P/Share
|
|
Aug 12
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
1,733
-3.77%
|
-
|
|
Aug 12
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
26,624
-10.2%
|
$3,727,360
$140.93 P/Share
|
|
Aug 12
2021
|
Ashley Cordova Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,624
+10.59%
|
$1,245,216
$34.13 P/Share
|
|
Aug 05
2021
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
1,000
-1.35%
|
$152,000
$152.5 P/Share
|
|
Aug 05
2021
|
Gabriel Leung |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.34%
|
$31,000
$31.45 P/Share
|
|
Aug 05
2021
|
Martin J. Madden |
SELL
Open market or private sale
|
Indirect |
34
-8.13%
|
$5,202
$153.13 P/Share
|
|
Aug 04
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
2,063
-2.71%
|
$305,324
$148.71 P/Share
|
|
Aug 03
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
464
-1.62%
|
$69,600
$150.11 P/Share
|
|
Aug 03
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
1,654
-2.12%
|
$246,446
$149.43 P/Share
|
|
Aug 03
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
328
-0.37%
|
$48,872
$149.43 P/Share
|
|
Aug 02
2021
|
William F Doyle Executive Chairman |
SELL
Open market or private sale
|
Direct |
995
-0.18%
|
$148,255
$149.38 P/Share
|
|
Aug 02
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
713
-0.79%
|
$106,237
$149.38 P/Share
|
|
Aug 02
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
536
-1.84%
|
$79,864
$149.38 P/Share
|
|
Jul 31
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,717
+4.16%
|
$572,418
$154.01 P/Share
|
|
Jul 30
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
651
-2.18%
|
$102,858
$158.96 P/Share
|
|
Jul 30
2021
|
Ely Benaim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
651
+2.14%
|
$54,033
$83.3 P/Share
|
|
Jul 06
2021
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
1,000
-1.35%
|
$183,000
$183.54 P/Share
|
|
Jul 06
2021
|
Gabriel Leung |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.34%
|
$31,000
$31.45 P/Share
|
|
Jul 06
2021
|
Todd Christopher Longsworth General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
154
+0.23%
|
$21,098
$137.12 P/Share
|
|
Jul 06
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
154
+0.2%
|
$21,098
$137.12 P/Share
|
|
Jul 06
2021
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118
+1.4%
|
$16,166
$137.12 P/Share
|
|
Jul 06
2021
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90
+0.31%
|
$12,330
$137.12 P/Share
|
|
Jul 06
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66
+0.04%
|
$9,042
$137.12 P/Share
|
|
Jul 06
2021
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100
+0.28%
|
$13,700
$137.12 P/Share
|
|
Jul 06
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
154
+0.17%
|
$21,098
$137.12 P/Share
|
|
Jul 06
2021
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
113
+0.35%
|
$15,481
$137.12 P/Share
|